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Abstract: 
 
GPR3, GPR6, and GPR12 are three orphan receptors that belong to the Class A family of G-
protein-coupled receptors (GPCRs). These GPCRs share over 60% of sequence similarity among 
them. Because of their close phylogenetic relationship, GPR3, GPR6, and GPR12 share a high 
percentage of homology with other lipid receptors such as the lysophospholipid and the 
cannabinoid receptors. On the basis of sequence similarities at key structural motifs, these 
orphan receptors have been related to the cannabinoid family. However, further experimental 
data are required to confirm this association. GPR3, GPR6, and GPR12 are predominantly 
expressed in mammalian brain. Their high constitutive activation of adenylyl cyclase triggers 
increases in cAMP levels similar in amplitude to fully activated GPCRs. This feature defines 
their physiological role under certain pathological conditions. In this review, we aim to 
summarize the knowledge attained so far on the understanding of these receptors. Expression 
patterns, pharmacology, physiopathological relevance, and molecules targeting GPR3, GPR6, 
and GPR12 will be analyzed herein. Interestingly, certain cannabinoid ligands have been 
reported to modulate these orphan receptors. The current debate about sphingolipids as putative 
endogenous ligands will also be addressed. A special focus will be on their potential role in the 
brain, particularly under neurological conditions such as Parkinson or Alzheimer’s disease. 
Reported physiological roles outside the central nervous system will also be covered. This 
critical overview may contribute to a further comprehension of the physiopathological role of 
these orphan GPCRs, hopefully attracting more research towards a future therapeutic 
exploitation of these promising targets. 
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Article: 
 
Introduction 
 
The molecular cloning of GPR3, GPR6, and GPR12 was reported over two decades ago (Saeki 
et al. [99] ; Eggerickx et al. [25] ; Song et al. [102] ). The genes encoding these three receptors 
were located in the human chromosomal regions 1p36.1, 6q21, and 13q12, respectively. Sharing 
a high percentage of sequence homology among them, GPR3, GPR6, and GPR12 form a 
subgroup of orphan class A GPCRs (GPR3/6/12) characterized by their high constitutive activity 
(Eggerickx et al. [25] ). Because of their phylogenetic relationship, GPR3/6/12 belongs to the so-
called MECA cluster (Fredriksson et al. [28] ; Fredriksson and Schio [29] ). This group of 
receptors is formed by the melanocortin receptors (MCRs), the endothelial differentiation G-
protein-coupled receptors (EDGR) [currently known as lysophospholipid receptors: sphingosine 
1-phosphate (S1PR) and lysophosphatidic acid (LPAR) receptors], the cannabinoid receptors 
(CBR), the adenosine binding receptors (AR), and the GPR3/6/12 orphan subset (Figure 1). 
According to the phylogenetic analysis reported by Fredriksson and coworkers, GPR3 and GPR6 
share chromosomal positions with the cannabinoid receptors, which suggests that they share a 
common ancestor (Fredriksson et al. [28] ). As detailed in subsequent sections, these receptors 
share common conserved motifs and specific structural features. 
 
 
Figure 1. Phylogenetic tree representation of the MECA cluster. The orphan subset GPR3/6/12 
is highlighted using the following color-coding: GPR3 in red; GPR6 in green; GPR12 in blue. 
 
Molecules potently and selectively targeting these receptors remain to be discovered. Very few 
small molecules have been identified as modulators of these GPCRs. Endocannabinoids such as 
anandamide or 2-arachidonoylglycerol failed to modulate these orphan receptors (Yin et al. 
[122]; Laun and Song [58] ) whereas cannabidiol (CBD) and other phytocannabinoids displayed 
activity at GPR3, GPR6, and/or GPR12 (Brown et al. [16] ; Laun and Song [58] ). Some 
sphingolipids have been proposed as putative endogenous ligands for GPR3, GPR6, and/or 
GPR12 (Uhlenbrock et al. [112] ; Ignatov et al. [44] , [45] ). However, due to the 
pharmacological inconsistencies reported among assays, the International Union of Basic and 
Clinical Pharmacology (IUPHAR) still categorizes these three receptors as orphans (Alexander 
et al. [6] ). 
 
Their close phylogenetic relationship with CB1 and CB2 along with the fact that they may share 
common ligands, led researchers to postulate a possible association between GPR3, GPR6, and 
GPR12 and the endocannabinoid system (Pertwee et al. [87] ). Nonetheless, extensive studies 
need to explore this relation, as well as, possible interactions among these GPCRs under specific 
physiopathological conditions. 
 
Within the past years, numerous studies have linked GPR3, GPR6, and GPR12 to several 
neurological processes, as well as other functions outside the brain such as oocyte maturation or 
metabolism. However, the lack of adequate pharmacological tools is delaying the elucidation of 
their biological relevance and their potential modulation in the treatment of diverse disorders. 
 
The current review intends to provide an organized and critical summary of the literature 
reported on the characterization of these attractive but complex orphan GPCRs. This global 
perspective may also help in analyzing their role and identifying novel approaches for further 
investigations. 
 
General features: structure and expression 
 
The orphan receptors GPR3, GPR6, and GPR12 are members of the rhodopsin-like class of 
GPCRs. These receptors, whose human sequences contain 330, 362, and 334 amino acids 
respectively, share about 60% of sequence identity among them. GPR3, GPR6, and GPR12 bear 
over 90% identity with their mouse and rat homologs. Sequence similarities at a transmembrane 
level with other GPCRs include over 45% homology with the lysophospholipid receptors LPA1, 
S1P1, and S1P5, and over 40% homology with the cannabinoid receptors CB1 and CB2.1 This 
high percentage of sequence homology with other lipid-sensing receptors of the MECA cluster 
leads them to share specific structural features and lack distinct motifs when compared to other 
receptor subfamilies. For instance, these receptors lack a helix kinking proline residues in the 
second and fifth transmembrane segments and have only one internal disulfide bridge in the 
second extracellular loop. GPR3, GPR6, and GPR12 also contain highly conserved residues in 
the transmembrane helices such as N1.50, D2.50, R3.50, W4.50, P6.50, and P7.50. In addition, 
they preserve the specific motifs present in TMH3, TMH6, and TMH7 which are DRY, CWXP, 
and NPXXY motifs, respectively (Morales et al. [77] ). 
 
Despite their structural similarities, sequence differences in specific transmembrane regions, 
extracellular and intracellular loops have been observed among GPR3, GPR6, and GPR12 (Isawi 
et al. [46] ). In fact, further structural understanding of these differences among receptors may 
help in designing future selective ligands for each of them. 
 
Although no crystal structure has been reported yet for any of these orphan receptors, 
computational molecular models are being developed based on GPCRs with currently available 
crystal structures (Morales et al. [77] ). These homology models take into consideration 
structural differences and similarities with other GPCRs while identifying potential binding 
pocket residues for GPR3, GPR6, and GPR12. This computational approach may lead to the 
optimization of known ligands and will aid future drug discovery. 
 
                                                          
1 http://gpcrdb.org/.  
The physiological role of GPR3, GPR6, and GPR12 is clearly defined by their high presence in 
the central nervous system (CNS) (Saeki et al. [99] ; Eggerickx et al. [25] ; Heiber et al. [35] ). 
As represented in Figure 2, GPR3 is highly expressed in hippocampus, hypothalamus, cerebral 
cortex, and cerebellum. Moreover, GPR6 is mainly located in striatum and hypothalamus, while 
GPR12 was detected in cerebral cortex, striatum, and cerebellum.2 
 
 
Figure 2. Schematic representation of GPR3, GPR6, and GPR12 expression. (A) Peripheral 
expression; (B) expression in the CNS. Color coding: GPR3 in red, GPR6 in green, GPR12 in 
blue; darker colors represent higher expression whereas lighter ones refer to lower expression. 
White circles refer to very low or no receptor expression. 
 
To a lesser extent, these GPCRs are also found in peripheral tissues. For instance, GPR3 is 
present in the eye, heart, breast, liver, ovary, testis, adipose tissue, and skin. However, in 
humans, GPR6 and GPR12 have very low expression at a peripheral level. GPR12 can be found 
in the eye, breast, liver, and skin, while low levels of GPR6 were detected in the stomach and 
testis.[ 2] It is worth mentioning that GPR3 and GPR12, but not GPR6, were detected in human 
umbilical vein endothelial cells (Uhlenbrock et al. [113] ). 
 
Even though similar expression patterns have been reported in other species, differences in 
particular tissues and cells have also been observed (Regard et al. [93] ). For instance, expression 
of GPR12 was detected in oocytes of rats and mice but not in humans (Hinckley et al. [37] ; 
DiLuigi et al. [23] ). 
 
In summary, since these receptors are highly expressed in human brain regions tightly associated 
with particular neurological disorders they could represent potential therapeutic targets. Detailed 
abnormal expression under certain pathological conditions will be described in the “Biological 
relevance” section. 
                                                          
2 https://www.proteinatlas.org/.  
 
Pharmacology 
 
A high constitutive activation of adenylyl cyclase has been consistently observed in GPR3, 
GPR6, and GPR12 (Eggerickx et al. [25] ; Uhlenbrock et al. [112] ; Martin et al. [68] ). In the 
absence of a ligand, the basal activity of these receptors was found to be similar to the activity of 
fully activated Gαs-coupled receptors with their corresponding modulators (Eggerickx et al. [25] 
; Uhlenbrock et al. [112] ). Experiments from diverse research groups demonstrated that these 
three receptors cause a significant increase in intracellular cAMP levels in a wide variety of cell 
lines (Eggerickx et al. [25] ; Uhlenbrock et al. [112] ; Ignatov et al. [45] ; Lobo et al. [63] ; 
Tanaka et al. [104] ). 
 
Besides their clear ability to couple to Gαs, GPR6 and GPR12 have also been reported to 
transduce their signal through Gαi/o. This G-protein promiscuity has been observed by 
independent research groups using different GPR6- or GPR12-transfected cell lines and a variety 
of functional outcomes (Uhlenbrock et al. [112] ; Ignatov et al. [44] , [45] ; Martin et al. [68] ). 
However, this G-protein dual coupling ability was not demonstrated for GPR3. 
 
To the best of our knowledge, there is no further evidence of these orphan receptors coupling 
with other Gα subunit partners. In fact, co-expression of GPR3, GPR6, or GPR12 with Gαq or 
Gα16 did not produce substantial intracellular Ca2+ release (Uhlenbrock et al. [112] ; Ignatov et al. 
[45] ). 
 
On the other hand, the G-protein independent β-arrestin2 signaling pathway has not been 
thoroughly investigated at these orphan receptors. GPR3 is the only receptor within this cluster 
for which this pathway was proved to be of special relevance under certain pathological 
conditions (Thathiah et al. [107] ). This will be further detailed in a following section (see 
“Biological relevance” section). 
 
At a molecular level, little is known about the mechanisms that control their signaling activity or 
potential subcellular localizations. Different reports demonstrated that GPR6 can signal from 
intracellular compartments. Prasad and collaborators confirmed the intracellular localization of 
GPR6 using multiple detection methods such as imaging assays, biotinylation or proteolytic 
enzymes using GPR6-HEK293 cells and striatal neurons (Padmanabhan et al. [85] ; Prasad et al. 
[91] ). Further assays demonstrated the Gαs-mediated constitutive activity of GPR6 suggesting its 
ability to signal from within the cell. 
 
In contrast, Lowther and coworkers suggested that GPR3 does not signal following endocytosis 
(Lowther et al. [64] , [65] ). They observed that GPR3 signals at the cell surface being 
susceptible to desensitization by a β-arrestin2 and GRK2 (G-protein-coupled receptor kinase)-
mediated mechanism. In fact, endocytic inhibition increased cAMP levels and GPR3 
accumulation at the cell-surface, whereas overexpression of GRK2 and β-arrestin2 led to lower 
cAMP levels and a reduced GPR3 cell-surface expression (Lowther et al. [65] ). 
 
Further biochemical mechanistic studies are clearly needed for a better pharmacological 
characterization of GPR3, GPR6, and GPR12. Advances in the development of specific 
antibodies and potent and selective ligands will certainly guide additional insights into 
downstream signaling events at these promising targets. 
 
Molecules targeting GPR3/6/12 
 
Thus far, very few ligands have been reported to modulate these orphan receptors. In fact, the 
lack of potent, efficacious, and selective GPR3, GPR6, and GPR12 ligands is delaying their 
therapeutical exploitation. Therefore, a structural understanding of these molecules and the 
identification of characteristic features might be crucial for further development of the desirable 
pharmacological tools. This section offers an overview of reported ligands and their 
pharmacology. 
 
Putative endogenous ligands 
 
A number of bioactive lipids have been inconclusively tested as potential endogenous molecules 
at GPR3/6/12 (Yin et al. [122] ; Southern et al. [103] ). Despite the lack of consensus, several 
reports point towards the lysophospholipids sphingosine 1-phosphate (S1P), dihydrosphingosine-
1-phosphate (DHS1P), and sphingosylphosphorylcholine (SPC) (Figure 3) as putative 
endogenous ligands for GPR3, GPR6, and/or GPR12. As detailed below for each particular 
receptor, divergent pharmacological reports are puzzling the deorphanization of these receptors. 
 
 
Figure 3. Structure of putative endogenous GPR3/6/12 ligands. 
 
S1P has been proposed as an endogenous GPR3 ligand in different reports. Uhlenbrock and 
coworkers firstly reported that S1P is able to activate GPR3 in hGPR3-HEK293 using 
intracellular Ca2+ mobilization and cAMP accumulation assays as readouts (Uhlenbrock et al. 
[112] ). Similar results were obtained in oocytes and mGPR3-COS7 supporting this data 
(Hinckley et al. [37] ; Zhang et al. [123] ). However, independent research groups were not able 
to confirm these results. S1P did not enhance GPR3 activity using cAMP assays in hGPR3-CHO 
cells (Valverde et al. [114] ), nor activate GPR3 in β-arrestin recruitment assays using transfected 
HEK293, CHO, or HeLa cells (Yin et al. [122] ; Southern et al. [103] ; Ye et al. [121] ). 
Regarding the sphingolipid SPC, not significant activity was found in the few assays reported so 
far (Uhlenbrock et al. [112] ). 
 
There are contradictory reports around considering S1P as the endogenous ligand for GPR6 as 
well. It has been demonstrated that in hGPR6-HEK293, S1P and DHS1P elicit intracellular 
Ca2+ mobilization, whereas no significant changes were observed on cAMP accumulation assays 
after S1P treatment (Uhlenbrock et al. [112] ). Ignatov and coworkers also observed that S1P 
induces an explicit boost in Ca2+ response in mGPR6-CHO cells, and stimulates GIRK in GPR6 
transfected frog oocytes (Ignatov et al. [45] ). According to these reports, S1P displays 
EC50 values in the nanomolar range at GPR6 (Uhlenbrock et al. [112] ; Ignatov et al. [45] ). On 
the other hand, in the β-arrestin PathHunter™ assay S1P did not show an ability to recruit β-
arrestin in GPR6 transfected HEK293 cells or CHO cells (Yin et al. [122] ; Southern et al. [103] 
). Independent assays showed that the bioactive molecule SPC displayed weak (Ignatov et al. 
[45] ) or no activity (Uhlenbrock et al. [112] ) at GPR6 when using Ca2+ mobilization assays. 
 
For GPR12, the endogenous debate is mainly focused on the lysophospholipid SPC. This lipid 
has been shown to induce significant Ca2+ mobilization in mGPR12-CHO, and to evoke GIRK-
mediated current in frog oocytes (Ignatov et al. [44] ). In both assays, SPC displays EC50 values 
in the nanomolar range. In contrast, other reports found that at GPR12 SPC produced weak or no 
effects on cAMP (Hinckley et al. [37] ), Ca2+ mobilization (Uhlenbrock et al. [112] ), or β-
arrestin recruitment assays (Yin et al. [122] ; Southern et al. [103] ), in mGPR12-COS7, 
hGPR12-HEK293, and hGPR12-CHO cell lines, respectively. On the other hand, S1P exhibited 
low (Uhlenbrock et al. [112] ; Ignatov et al. [44] ) or no efficacy (Yin et al. [122] ; Southern 
et al. [103] ) at GPR12 in the reported assays. 
 
Interestingly, the Japanese company Teijin Pharma Limited reported that the neuropeptide 
Nesfatin-1 (Dore et al. [24] ) is also able to activate GPR12 (Mori and Eguchi [79] ). This was 
proved through cAMP accumulation and CREB phosphorylation assays in mGPR12-HeLa and 
mGPR12-CHO cells, respectively. 
 
It is also worth mentioning that endogenous cannabinoid ligands were also tested at GPR3, 
GPR6, and GPR12. In particular, anandamide, 2-arachidonoylglycerol, virodhamine, and noladin 
ether were assessed using β-arrestin recruitment assays, but no activity was observed at 
micromolar concentrations (Yin et al. [122] ; Laun and Song [58] ). 
 
To sum up, the reported results point to the aforementioned sphingolipids as the putative 
endogenous ligands for these receptors. The controversial pharmacological data may rely on the 
intrinsic properties of each GPCR, as well as, on the differences among cell-types and functional 
outcomes. Experimental issues such as the poor solubility of these lipids, or the possible 
presence of other lipids in the cell media, can also be causing some of these functional 
discrepancies. Therefore, so far no endogenous ligand has been confirmed for GPR3, GPR6, or 
GPR12, which are still classified as Class A orphan receptors. 
 
Exogenous ligands 
 
The identification of small molecules targeting GPR3, GPR6, and GPR12 is crucial for the 
understanding of the physiological role of these receptors. Despite the screening efforts done by 
academic researchers and pharmaceutical companies, limited hit compounds have been 
discovered so far. Natural products such as CBD or tyrosol, or chemotypes of synthetic origin 
such as triazolopyrimidines or pyrazines are among the compounds currently known. Table 1 
provides an overview of all the molecules covered in this section. 
 
Table 1. Summary of GPR3/6/12 ligands and their functionality. 
 Functionality   
Ligands GPR3 GPR6 GPR12 Functional readout References 
DPI Agonista NA NA cAMP accumulation Ye et al. (2014) 
    β-arrestin2 recruitment  
    Ca2+ mobilization  
AF64394 Inverse agonistb Inverse agonista Inverse agonista cAMP accumulation Jensen et al. (2014) 
CBD Inverse agonista Inverse agonista NR β-arrestin2 recruitment Laun and Song (2017) 
 NR NR Inverse agonista cAMP accumulation Brown et al. (2017) 
415 NR Inverse agonistb NR cAMP accumulation Hitchcock et al. (2014) 
494 NR Inverse agonistb NR cAMP accumulation Hitchcock et al. (2014) 
633 NR Inverse agonistb NR cAMP accumulation Hitchcock et al. (2014) 
5 NR Inverse agonistb NR cAMP accumulation Hitchcock et al. (2015) 
47 NR Inverse agonista NR cAMP accumulation Brown et al. (2015) 
25 NR Inverse agonista NR cAMP accumulation Adams et al. (2015) 
ARE111 NR Inverse agonista NR cAMP accumulation Beeley et al. (2001) 
    GTPγ binding  
ARE112 NR Inverse agonista NR cAMP accumulation Beeley et al. (2001) 
    GTPγ binding  
ARE133 NR Inverse agonistb NR cAMP accumulation Beeley et al. (2001) 
    GTPγ binding  
ARE136 NR Inverse agonistb NR cAMP accumulation Beeley et al. (2001) 
    GTPγ binding  
Tyrosol NR NR Agonistb cAMP accumulation Lin et al. (2008) 
NA, no activity found at the concentrations tested; NR, non-reported. 
a Potency in the micromolar range. 
b Potency in the nanomolar range. 
  
 
Figure 4. Structure of the GPR3 agonist DPI. 
 
Diphenyleneiodoniumchloride 
 
Diphenyleneiodoniumchloride (DPI, Figure 4), a known inhibitor of NADPH oxidase (NOX) 
(Aldieri et al. [4] ), was identified as the first small molecule acting as an agonist of GPR3 (Ye 
et al. [121] ). This ligand was discovered from a screening of over 40,000 compounds, showing 
the best agonist dose-dependent activity with EC50 values in the low micromolar range. DPI was 
shown to promote GPR3 activation through different signaling pathways such as intracellular 
cAMP accumulation, Ca2+ mobilization, membrane recruitment of β-arrestin2, and receptor 
desensitization. Interestingly, DPI did not display activity GPR6 and GPR12. 
 
 [1,2,4]Triazolo[1,5-α]pyrimidine scaffold 
 
The [1,2,4]triazolo[1,5-α]pyrimidine scaffold emerged as a promising GPR3 chemotype from a 
high throughput screen of the Lundbeck screening collection (Jensen et al. [48] ). The 
identification of compound 1 (Figure 5) as a micromolar inverse agonist of GPR3 inspired the 
development of a series of triazolopyrimidines in order to fine-tune activity and potency. 
Numerous derivatives modifying the central bicyclic core, as well as, both phenyl substituents 
were synthesized and pharmacologically tested. Structure-activity relationships helped to 
optimize the aromatic substitution pattern at the benzyl group and to understand pharmacophoric 
requirements such us the presence of a 5-aryl substituent. Among the novel triazolopyrimidine 
derivatives reported, AF64394 (Figure 5) was the most promising hit identified using 
homogeneous time-resolved fluorescence (HTRF) cAMP assays in hGPR3-HEK293 cells. This 
compound was shown to act as a GPR3 inverse agonist with an IC50 value in the mid-nanomolar 
range. AF64394 showed weak activity at GPR6 or GPR12, but no activity at other class A 
GPCRs (Jensen et al. [48] ). 
 
 
Figure 5. . Structure of the first triazolopyrimidine identified as a GPR3 inverse agonist, 
compound 1, and its optimized analog AF64394. 
  
Cannabidiol and derivatives 
 
The well-known phytocannabinoid cannabidiol (CBD, Figure 6) has recently been identified as a 
modulator of GPR3, GPR6, and GPR12. This non-psychoactive cannabinoid has been shown to 
act as an inverse agonist at GPR3 and GPR6 using β-arrestin2 recruitment assays (Laun and 
Song [58] ). The same authors later reported that CBD also displays Gαs-mediated inverse 
agonism at GPR12 using cAMP accumulation assays (Brown et al. [16] ). However, CBD does 
not exhibit high potency at these orphan receptors presenting micromolar IC50s. CBD-related 
compounds such as cannabidivarin (CBDV, Figure 6) and cannabidiol-2′,6′-dimethyl ether 
(CBDD, Figure 6) were also tested at GPR12 showing lower activity than CBD (Brown et al. 
[16] ). From the limited GPR12 reported SAR, we can infer that the free hydroxyl groups and the 
pentyl alkyl chain are crucial for CBD’s activity at this receptor. 
 
 
Figure 6. Structure of CBD and its related analogs CBDV and CBDD. 
 
The pharmacology of CBD is complex given its many reported potential therapeutic uses 
(Morales et al. [78] ; Pisanti et al. [90] ; Watt and Karl [118] ); its low to moderate activity at 
GPR3, GPR6, and GPR12 may contribute to CBD’s properties under certain pathological 
conditions. 
 
It is also important to underscore that related phytocannabinoids, Δ9-tetrahydrocannabinol, 
cannabinol, and cannabigerol among them, were also evaluated at these receptors, but they did 
not exhibit activity at the concentrations tested in cAMP accumulation or β-arrestin2 recruitment 
assays (Brown et al. [16] ; Laun and Song [58] ). Additionally, synthetic cannabinoid ligands 
such as HU-210, CP55,940 and WIN55,212-2 were assessed at GPR12 (Brown et al. [16] ). 
These compounds were able to inhibit cAMP accumulation, but only at high micromolar 
concentrations. 
  
Pyrazine derivatives 
 
Patents from Envoy Therapeutics, Inc. and Takeda Pharmaceutical Company have claimed the 
use of a wide range of pyrazine analogs as GPR6 modulators (Hitchcock et al. [39] ; Adams et al. 
[3] ; Brown et al. [15] ; Hitchcock et al. [38] ). These inventions claim their use as inverse 
agonists of GPR6 in the treatment of neurological pathologies such as Parkinson’s disease (PD), 
Huntington’s disease (HD), and other dyskinesias. The first patent in which this scaffold was 
identified for the modulation of GPR6 was published in 2014 by Envoy Therapeutics, Inc 
(Hitchcock et al. [39] ). This patent presents over 600 bicyclic pyrazine derivatives. Among the 
most potent GPR6 modulators reported were the quinoxaline 415, the pyrido[3,4-b]pyrazine 494, 
and the pyrazino[2,3-d]pyridazine 633 (Figure 7, the number assigned to each compound relates 
to the example number reported in the patent). According to cAMP accumulation assays in 
hGPR6-CHO cells, these three compounds are GPR6 inverse agonists and display IC50 values in 
the low nanomolar range. Compound 415 was further tested in vivo in a PD rodent model of 
haloperidol-induced catalepsy. Remarkably, catalepsy was significantly reduced in a dose-
dependent manner after intraperitoneal treatment with 415. Structural modifications on the 
central pyrazine core and its substituents led to the subsequent three patents reported by Takeda 
Pharmaceutical Company (Adams et al. [3] ; Brown et al. [15] ; Hitchcock et al. [38] ). Novel 
pyrazino[2,3-d]pyridazines such as 5 showed similar activity to the previous compounds 
(Hitchcock et al. [38] ). However, efforts on tetrahydropyrazines (Brown et al. [15] ) or non-
bicyclics (Adams et al. [3] ) led to a decrease in potency and efficacy at GPR6. For instance, 
compounds 47 and 25 (Figure 7) showed IC50 values in the micromolar range. 
 
 
Figure 7. Structures of the selected pyridazine analogs that modulate GPR6. 
 
All of these patents provide evidence for the potential of the pyrazine scaffold in the 
development of GPR6 ligands. Nonetheless, selectivity among GPCRs and their activity at other 
transduction pathways needs to be further investigated. 
  
Imidazolidinethiones and imidazodithiazoles 
 
In 2001 Arena Pharmaceuticals, Inc. patented imidazolidinethione and imidazodithiazole 
derivatives as GPR6 inverse agonists indicating their potential use in the treatment of obesity 
(Beeley et al. [9] ). In an initial screening using GTPγS and cAMP assays, compounds ARE111 
and ARE112 (Figure 8) were identified as hit molecules with IC50 values in the micromolar 
range. Synthetic fine-tuning of these hits led to the discovery of the GPR6 inverse agonists 
ARE133 and ARE136 (Figure 8), which display nanomolar activity. Compound ARE112 was 
also tested in vivo demonstrating capacity to reduce body weight and food intake in a rat model 
(Beeley et al. [9] ). 
 
 
Figure 8. Structures of imidazolidinethiones ARE111 and ARE133, and imidazodithiazoles 
ARE112 and ARE136. 
  
Tyrosol 
 
The phenylethanoid antioxidant tyrosol (Figure 9) was identified as a GPR12 ligand by Lin and 
coworkers (2008). In this study, 15 natural products, extracted after isolation of endophytic 
Streptomyces sp. from a root of Cistanche deserticola, were evaluated using cAMP assays in 
hGPR12-CHO cells. Tyrosol was the only compound that promoted a GPR12-mediated increase 
on intracellular cAMP levels at a concentration of 100 nM. These findings indicate that tyrosol 
may be considered a GPR12 ligand and a potential scaffold for the development of more potent 
GPR12 modulators (Lin et al. [62] ). 
 
 
Figure 9. Structure of the GPR12 modulator tyrosol. 
 
The following table summarizes the reported activity of the GPR3, GPR6, and/or GPR12 
modulators published thus far. 
  
Table 2. Summarized table of the physiopathological role of GPR3, GPR6, and GPR12. 
Target Physiopathological role Implication References 
GPR3 Alzheimer’s disease Inhibition of amyloid pathology Thathiah et al. (2009)  
Multiple sclerosis Potential biomarker Hecker et al. (2011)  
Neurite outgrowth Promotion of neurite outgrowth and cerebellar 
development 
Tanaka et al. (2014) 
 
Neuropathic pain Regulation of neuropathic pain and morphine-induced 
antinociception 
Ruiz-Medina et al. (2011) 
 
Cell survival Induction of neuronal survival and antiapoptotic 
properties 
Tanaka et al. (2007, 2014) 
 
Stress GPR3 deletion triggers anxiety-like and depression-like 
behavior 
Valverde et al. (2009) 
 
Metabolic disorders Impairment of thermogenic response of iBAT and late-
onset obesity 
Godlewski et al. (2015) 
 
Oocyte maturation Regulation of meiosis Mehlmann et al. (2004) 
GPR6 Alzheimer’s disease Involvement in the neuroprotective effect of C1q protein Benoit et al. (2013)  
Parkinson’s disease GPR6 deletion impacts motor symptoms Oeckl et al. (2014)  
Huntington’s disease GPR6 is downregulated in HD brain Hodges et al. (2006)  
Schizophrenia Impairment of striatum P-DARPP-32 Oeckl et al. (2014)  
Instrumental learning Regulation of instrumental performance Frank and Fossella (2011) and 
Collins and Frank (2012)  
Cell survival Antiapoptotic properties Ignatov et al. (2003b) 
GPR12 Neurite outgrowth Promotion of neurite outgrowth Tanaka et al. (2007, 2014)  
Pain Sensitivity to heat-related pain Carlton et al. (2006)  
Cell survival Antiapoptotic properties Adams and Cory (2007), Lu 
et al. (2012a, 2012b)  
Cognitive functions Regulation of long-term memory Peters et al. (2008)  
Metabolic disorders Appetite control in murine obesity models Brennand et al. (2001)  
Oocyte maturation Regulation of meiosis (only in rodents) Hinckley et al. (2005) 
Biological relevance 
 
The physiological roles of GPR3, GPR6, and GPR12 have not been fully elucidated. However, 
the increasing research published in the last decade has widely demonstrated the relevance of 
GPR3, GPR6, and/or GPR12 in a variety of neurological disorders. As previously mentioned, 
these orphan receptors are highly expressed in particular regions of the brain. This expression 
pattern is often abnormally regulated under certain physiopathological conditions. Even if their 
therapeutic potential remains to be fully understood, it is likely that GPR3, GPR6, and GPR12 
represent promising targets for the management of the pathological processes described below. 
Table 2 summarizes the physiopathological implications of each receptor. 
 
Alzheimer’s disease 
 
Alzheimer’s disease (AD) is a progressive and chronic brain disorder that accounts for over 60% 
of the cases of dementia and is the sixth leading cause of death in the USA.3 This 
neurodegenerative disease is initially characterized by short-term memory loss and progressive 
impairment of most cognitive functions (Mattson [71] ). The etiology of this pathology is 
associated with the loss of neurons and synapses due to the formation of amyloid plaques and 
neurofibrillary tangles. These plaques are caused by the accumulation of proteinaceous 
aggregates composed of amyloid-β (Aβ) peptides (mainly Aβ1-42 but also Aβ1-40 peptides), 
whereas the neurofibrillary tangles are caused by hyperphosphorylation of the microtubule-
associated protein Tau (LaFerla et al. [57] ; Karran et al. [50] ). 
 
In 2009, Thathiah and coworkers identified a link between GPR3 and AD using a high-
throughput functional genomics screen (Thathiah et al. [108] ). This receptor was found to 
modulate one of the aforementioned pathological hallmarks of AD: Aβ peptide generation. In 
vitro and in vivo studies in AD models demonstrated that GPR3 overexpression triggers an 
increase in Aβ production, while depletion of this receptor prevents Aβ aggregation. Both Aβ1-
40 and Aβ1-42 levels increased in a dose dependent manner with GPR3 expression. Moreover, the 
expression of GPR3 is elevated in the postmortem brain of sporadic AD patients and this 
upregulation correlates with the progression of the disease (Thathiah et al. [108] ; Huang et al. 
[43] ). 
 
Subsequent findings from the same research group provided further validation of the role of 
GPR3 in AD (Thathiah et al. [107] ; Huang et al. [43] ). An array of functional experiments 
proved that GPR3 regulates Aβ generation via β-arrestin2 via a G-protein-independent 
mechanism (Thathiah et al. [107] ). Mutation of the serine amino acids in the C-terminus of 
GPR3, residues associated with β-arrestin2 recruitment after phosphorylation, resulted in a 
reduction of Aβ1-40 and Aβ1-42 peptide release, thus confirming that the GPR3 β-arrestin2 
pathway is essential for Aβ production. This association was also observed in β-arrestin2 
knockout mice since GPR3 only increased Aβ production in the presence of β-arrestin2 in the 
wild-type (WT) mice (Thathiah et al. [107] ). 
 
Pursuing a translational approach, the effect of GPR3 was examined in four different AD 
transgenic mice models (Huang et al. [43] ). An exploration of the role of this receptor in 
                                                          
3 https://www.alz.org/facts/.  
amyloid pathology, as well as, in behavioral studies was undertaken. In the four mice models, 
GPR3 deletion reduced amyloid plaque burden and deposition as observed in the cortex and 
hippocampus of these animals. Furthermore, behavioral tests assessing neuromotor coordination, 
learning and memory capacities, showed that GPR3 genetic ablation alleviates cognitive deficits 
in AD transgenic mice. Overall, all these results suggest that this orphan receptor is a potential 
target to be explored in the challenging task of combating AD. 
 
GPR6 was also reported to have a role in the development of AD via the C1q complex (Benoit 
et al. [10] ). The C1q complex is a protein complex that is part of the classical complement 
pathway (Reid [94] ) present in the innate immune system. C1q was found to be associated with 
AD as it is upregulated in AD models (Alexander et al. [5] ; Melchior et al. [75] ; Howell et al. 
[42] ). Furthermore, C1q is involved in preventing the neurotoxic effect of fibrillar amyloid-sz 
(fAsz) in vitro (Pisalyaput and Tenner [89] ), and it has neuroprotective abilities in early stages 
of AD models (Benoit and Tenner [11] ; Benoit et al. [10] ). 
 
The neuroprotective properties of C1q are induced by several mechanisms (Kouser et al. [54] ). 
One of them is modulating GPR6 gene expression. In fAsz-injured neurons, the neuroprotective 
effect of C1q is accompanied by an increased expression of GPR6. In contrast, the 
neuroprotective capacity of C1q is diminished when GPR6 is silenced. The same increase in 
GPR6 expression was exhibited in vivo in the hippocampus of 2-4 months old AD transgenic 
mice (Benoit et al. [10] ). The contribution of GPR6 in this process may arise from the elevated 
levels of intracellular cAMP production triggered by its increased expression (Heiber et al. [35] ; 
Uhlenbrock et al. [112] ). These high levels of cAMP may increase the activation of the central 
transcription factor pCREB and its subsequent neurotrophic effect (Tong [109] ; Kokubo et al. 
[52] ). 
 
Additionally, it is worth mentioning that the biotechnology company Galapagos N. V. patented a 
method for identifying inhibitors of Aβ production by measuring their potential to modulate 
GPR3, GPR6, and/or GPR12 (Hoffmann et al. [41] ). 
 
Much work remains to be done in the elucidation of the role of these receptors in the pathology 
of AD. However, we can clearly underscore GPR3 as a potential therapeutic target for the 
treatment of this neurodegenerative disorder. Pharmacological modulation of this receptor using 
a G-protein independent, β-arrestin2 biased inverse agonist may provide a significant reduction 
in the amyloid plaques that characterize this disease. 
  
Parkinson’s disease 
 
Parkinson’s disease (PD) is a neurodegenerative disorder that impacts the motor system causing 
distinctive symptoms such as tremors, akinesia, bradykinesia, and rigidity. PD is pathologically 
characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc) and Lewy bodies aggregation (Olanow and Tatton [84] ; Jankovic [47] ). This cell 
degeneration impairs the striatonigral and the striatopallidal medium spiny neurons (MSNs), 
causing dysfunctions in motor coordination (Kreitzer and Malenka [56] ). 
 
The role of GPR6 in PD arises from its high expression in the striatum, especially in 
striatopallidal neurons (Lobo et al. [63] ; Heiman et al. [36] ; Komatsu et al. [53] ). Oeckl and 
collaborators studied the neurochemical and behavioral effects of GPR6 ablation in mice (Oeckl 
et al. [82] ). GPR6−/− mice showed a decrease of striatal cAMP. In addition, mice lacking GPR6 
showed an increase of dopamine concentration in the striatal tissue, while extracellular dopamine 
levels were not detected to vary. Motor function effects were also observed in these animals. 
GPR6−/− mice showed higher locomotor activity in the open field with and without haloperidol 
treatment, a dopamine D2 antagonist that decreases locomotor activity. 
 
Moreover, these authors explored the role of GPR6 in a hemiparkinsonism 6-OHDA (6-
hydroxydopamine) mice model. In the absence of GPR6, 6-OHDA mice display a decrease in 
abnormal involuntary movements suggesting the potential of this receptor in dyskinesia (Oeckl 
et al. [82] ). Dyskinesia is one of the undesirable outcomes of current dopamine PD therapies 
(Calabresi et al. [19] ); therefore, a GPR6 modulator may offer an anti-dyskinesia alternative to 
dopamine replacement therapy. 
 
In a recent report, the same research group investigated the role of GPR6 in a PD rodent model 
generated by the dopaminergic neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) (Oeckl and Ferger [81] ). GPR6 ablation in these PD mice induced a more 
prominent reduction in dopamine and 4-hydroxy-3-methoxyphenylacetic acid (HVA). 
Furthermore, an increase in dopamine turnover was detected in these mice. A significantly 
higher reduction of the number of tyrosine hydroxylase (TH)-positive neurons in the SNpc was 
also observed in GPR6−/− mice when compared with their WT counterparts. These findings 
indicate that GPR6 enhances the dopaminergic neurodegeneration induced by MPTP at a striatal 
level. Taken together the results reported by Oeckl and coworkers suggest that pharmacological 
modulation of GPR6 might represent a novel approach for the treatment of PD. 
 
As previously mentioned (exogenous ligands section), patents from Envoy Therapeutics, Inc. and 
Takeda Pharmaceutical Company (Hitchcock et al. [39] ; Adams et al. [3] ; Brown et al. [15] ; 
Hitchcock et al. [38] ) also claimed the use of GPR6 inverse agonists in the treatment of PD. 
They showed that pyrazine derivatives are able to reduced haloperidol-induced catalepsy in a 
rodent PD model. 
 
Even if these data provide solid indications about PD, different models should be used to further 
demonstrate the relationship between GPR6 and PD and to understand the potential modulation 
of GPR6 as a molecular target for the treatment of PD. 
  
Huntington’s disease 
 
Huntington’s disease (HD) is a hereditary disorder that causes a gradual loss of neurons in the 
basal ganglia (BG), especially in the striatum. Its symptoms are characterized by mood swings, 
jerky uncontrollable movements, and obsessive-compulsive behavior (Roos [97] ). 
 
The neurological dysfunction that HD patients suffer affects the classical pathways of the BG. 
The striatopallidal pathway MSNs is impaired by this pathology leading to incessantly 
involuntary motions (Raymond et al. [92] ). 
 
Two independent research groups provided evidence of the relation between GPR6 and the HD 
pathology (Hodges et al. [40] ; Le Gras et al. [59] ). Analysing 44 human HD brains, Hodges and 
coworkers observed a significant decrease in GPR6 expression compared to unaffected controls 
(Hodges et al. [40] ). Similarly, in a recent study of striatal transcriptional alterations in HD, the 
authors detected that the expression of GPR6 eRNA (enhancer RNA) is deregulated in R6/1 HD 
mouse striatum (Le Gras et al. [59] ). They further demonstrated that GPR6 expression is 
reduced in the striatum of R6/1 and Q140 HD mice models. 
 
Although more research is clearly required, this data suggests that GPR6 may have a role in HD 
pathology. Therefore, modulation of GPR6 could be a useful therapeutic intervention in the 
treatment of this disease. 
  
Schizophrenia 
 
Schizophrenia is a long-term psychiatric illness characterized by dysregulation of 
neurotransmitters such as dopamine, glutamate, serotonin, and GABA in specific brain regions. 
Its common symptoms include hallucinations, delusions, disorganized thinking, and lack of 
motivation (Patel et al. [86] ). 
 
One of the proteins that has been embroiled in schizophrenia pathophysiology is the dopamine 
and cAMP-regulated phosphoprotein DARPP-32 and its phosphorylated version P-DARPP-32. 
DARPP-32 and P-DARPP-32 are present in the striatum, especially in MSNs, where they are 
involved in neo-striatum signaling that affects locomotor behavior (Wang et al. [117] ). 
 
Interestingly, in GPR6−/− mice, Oeckl and coworkers observed a twofold increase in striatum P-
DARPP-32 with no alterations in DARPP-32 expression (Oeckl et al. [82] ). A decrease in 
striatal cAMP levels was also detected in these experiments. Therefore, these results suggest that 
cAMP-independent mechanisms influence DARPP-32 phosphorylation in mice lacking GPR6. 
 
This correlation between GPR6 deletion and P-DARPP-32 only provides the first evidence of the 
possible implication of this receptor in the treatment of schizophrenia. However, further studies 
need to identify the effect of GPR6 deficiency on schizophrenia models to provide a clear 
explanation of its relation with DARPP-32 phosphorylation. 
  
Multiple sclerosis 
 
Multiple sclerosis (MS) is an inflammatory and degenerative chronic disorder that affects the 
central nervous system. Even though the cause is not yet clear, its underlying mechanism is 
characterized by progressive damage to the myelin sheath (demyelination), impairing the 
conduction of signals between the impacted nerves. This pathology translates into numerous 
symptoms such as loss of muscle coordination, weakness, numbness, and problems with speech, 
vision, and bladder control. 
 
Despite the current advances in the field, available drugs are only partially effective, and many 
patients experience relapses in progressive forms of the disease (Vosoughi and Freedman [115] ; 
Torkildsen et al. [110] ). Therefore, there is a clear need for individual molecular biomarkers to 
better monitor disease evolution and predict therapy response (Graber and Dhib-Jalbut [33] ; 
Coyle [22] ). In this context, Hecker and coworkers explored possible disease progression 
markers in the blood of MS patients (Hecker et al. [34] ). They studied an array of 110 genes as 
potential predictive biomarkers using data sets including 148 subjects. Among these analyzes, 
only GPR3 and IL17RC, a cytokine receptor which binds interleukin 17A (Yao et al. [120] ), 
were validated as potential blood markers of disease progression. Interestingly, the expression of 
GPR3 was significantly reduced in patients with poor disease progression (more relapses and/or 
disability increase) in all data sets. Therefore, GPR3 revealed to have a high prognostic value for 
MS long-term progression (Achiron et al. [1] ; Hecker et al. [34] ). Similar results were recently 
observed in another study performed with a group of 87 Egyptian MS patients (Massoud et al. 
[70] ). However, in a study of whole blood samples of 20 relapsing-remitting MS patients, 
investigators could not confirm a significant reduction in GPR3 expression (Martire et al. [69] ). 
 
Therefore, further studies are required to validate the potential of GPR3 as a candidate biomarker 
for MS progression. Additional functional studies along with an evaluation of how GPR3 
depletion affects MS symptoms in animal models may help verify a specific role for GPR3 in 
this pathology. 
  
Neurite outgrowth 
 
Neurite outgrowth is one of the essential processes that take place during embryonic 
development and regeneration of the mammalian nervous system. This process is characterized 
by the formation of new projections and neurite elongation during neuronal migration and 
differentiation (Khodosevich and Monyer [51] ). 
 
Multiple publications demonstrated that cAMP regulates neurite outgrowth (Cai et al. [18] , [17]; 
Gao et al. [31] ). This finding attracted attention towards the GPR3/6/12 cluster of receptors due 
to their high constitutive activity and their high abundance in the CNS (Saeki et al. [99] ; 
Eggerickx et al. [25] ; Ignatov et al. [45] ). Tanaka and collaborators were the first group that 
provided evidence of the relation between these receptors and neurite outgrowth (Tanaka et al. 
[104] ). In primary cultures of rat cerebellar granule neurons (CGNs), transfection of GPR3, 
GPR6 and GPR12 was shown to promote a significant enhancement of neurite outgrowth. 
GPR12 exhibited the highest increment among the three receptors, exerting its effect by a 
Gαs and cAMP-dependent protein kinase (PKA) dependent pathway. 
 
Interestingly, GPR3 was shown to be highly expressed in developing rat CGNs, particularly in 
the internal granule layer. Knocking down endogenous GPR3 in the CGN resulted in a 
substantial decrease in neurite outgrowth. Cotransfection of either GPR3 or GPR12 was shown 
to counteract this reduction (Tanaka et al. [104] ). 
 
Further reports from this group focused on investigating the role of GPR3 in CGN (Tanaka et al. 
[106] , [105] ; Miyagi et al. [76] ). These studies showed that this orphan receptor can modulate 
proliferation and differentiation of cerebellar granule precursors in postnatal development of 
rodent cerebellum (Tanaka et al. [106] ). Further mechanistic insights showed that during 
development, GPR3 activates the ERK (extracellular signal-regulated protein kinase) and Akt 
(protein kinase B) signaling pathways. Through these mechanisms, GPR3 is able to protect 
neurons from apoptosis (Tanaka et al. [105] ). 
 
Additional studies demonstrated that in rodent CGN GPR3 can induce upregulation of PKA. 
Using time-lapse analyzes, it was shown that GPR3 is dynamically moved along the neurite tip 
contributing to local PKA activation in CGN development (Miyagi et al. [76] ). Therefore, these 
results suggest the involvement of GPR3 in crucial neuronal functions, including differentiation 
and maturation. 
 
A different research group investigated the role of GPR12 overexpression in rat 
pheochromocytoma PC12 cells (Lu et al. [66] ). They observed that GPR12 promotes neurite 
outgrowth by inducing differentiation of PC12 into neuron-like cells (increased cell body 
diameter and neurite length). This effect was accompanied by a significant increment in the 
expression of multiple neurite outgrowth-related markers (Bcl-xL, Bcl-2, and synaptophysin), 
and increased ERK1/2 phosphorylation (Lu et al. [66] ). 
 
These reports provide the basis for further investigation of the potential modulation of these 
orphan receptors in mediating neurite outgrowth and cerebellar development. Targeting these 
GPCRs may provide a beneficial approach for the treatment of several neurological afflictions or 
injuries. 
  
Instrumental conditioning 
 
Human behavior is continuously adjusted by learning and operating processes. The fundamental 
principles of behaviorism are related to Pavlovian and instrumental conditioning. Pavlovian 
conditioning is based on pairing a biological stimulus with a previously neutral action. 
Instrumental conditioning implies that in the process of learning there is an association between 
behaviors and specific events such as rewards or punishments (Balleine and Dickinson [8] ). 
 
As mentioned above, GPR6 is highly expressed in striatopallidal neurons (Lobo et al. [63] ; 
Heiman et al. [36] ; Komatsu et al. [53] ). Given the importance of striatal involvement in 
instrumental conditioning (Balleine [7] ), Lobo and coworkers decided to explore the role of 
GPR6 in learning processes (Lobo et al. [63] ). In a reward instrumental conditioning assay, WT 
and GPR6−/− food-deprived mice were trained to bar press for sweet pellets. GPR6−/− mice 
displayed a lower latency time to press the bar than their WT littermates. Likewise, after more 
extensive training, GPR6−/− mice reached a higher rate of asymptotic performance. In contrast, 
using an appetitive Pavlovian conditioning procedure, GPR6 WT and GPR6−/− mice showed 
comparable results. This data indicates that GPR6 has no effect on Pavlovian conditioning, but it 
is an important striatopallidal regulator on instrumental conditioning. 
 
Furthermore, by analyzing single nucleotide polymorphisms (SNPs) Frank and collaborators 
identified GPR6 as a genetic marker of BG (Frank and Fossella [27] ; Collins and Frank [21] ). 
In this study, GPR6 was shown to influence reinforcement learning rate on instrumental learning 
models. 
 
Overall, GPR6 seems to play a role in instrumental performance in mammals. Mechanism, 
function, and possible therapeutic intervention remain to be studied. 
  
Other neurological implications 
 
In addition to the neurodegenerative disorders and neural functions detailed thus far, these 
orphan receptors have been also implicated in additional brain-related processes such as 
neuropathic pain, modulation of the early phases of cocaine reinforcement, or cell proliferation. 
  
Pain 
 
Pain mitigation and screening for new molecular targets for antinociception have been a priority 
among researchers for decades. Both GPR3 and GPR12 have been suggested to play a role in 
pain modulation. 
 
Ruiz-Medina and coworkers identified a relation between GPR3 and neuropathic pain (Ruiz-
Medina et al. [98] ). GPR3 was shown to be related to the development and expression of 
neuropathic pain after sciatic nerve ligature. GPR3−/− mice that suffered a sciatic nerve injury 
exhibited an increase in sensitivity toward thermal noxious and non-noxious stimuli in both the 
plantar and cold-plate tests. Additionally, through tail immersion tests in GPR3 WT and 
GPR3−/− mice, they demonstrated that this orphan receptor is implicated in the analgesia induced 
by morphine. This suggested that GPR3 is a novel component of a pro-opioid receptor system. 
These results underscore GPR3 as a potential candidate for the treatment of pain. 
 
GPR12 has been associated with this pathological condition as well. The company Paradigm 
Therapeutics Limited patented the use of GPR12 modulators for the manipulation of the 
neuronal and limbic systems and pain treatment (Carlton et al. [20] ). In this patent, 
GPR12−/− mice were found to be more sensitive to heat-induced pain in the tail flick and hot 
plate tests than WT mice. 
 
These two reports open future avenues for investigating GPR3 and GPR12 in the development of 
neuropathic pain processes. 
  
Cell proliferation and survival 
 
Diverse studies have demonstrated the participation of GPR3, GPR6, and GPR12 in the control 
of cell survival and proliferation. 
 
As previously described, Tanaka and collaborators showed that in CGNs these three orphan 
GPCRs can promote neuronal survival and display antiapoptotic effects (Tanaka et al. [105] ). 
Only GPR3 revealed neuronal antiapoptotic capabilities under a variety of apoptotic stimuli such 
as hypoxia or reactive oxygen species. As demonstrated in rat CGNs cultures, GPR3 mediates 
this antiapoptotic effect via PKA, ERK, and Akt signaling pathways. These results suggest that 
the modulation of GPR3 may represent a potential neuroprotective strategy against brain 
ischemia 
 
Ignatov and coworkers also contributed to this topic studying the implication of GPR6 in 
apoptotic cell death (Ignatov et al. [45] ). They showed that under serum deprivation or 
H2O2 apoptosis-inducing stimuli, the presence of S1P causes higher cell viability in GPR6-CHO 
cells compared to vector-transfected cells. They proposed that GPR6 causes this antiapoptotic 
effect through the activation of sphingosine kinase and mitogen-activated protein kinase 
(MAPK). 
 
Regarding GPR12, antiapoptotic properties have also been reported under stress conditions. 
GPR12 heterologous expression was shown to promote cell proliferation in GPR12-HEK293 
cells under serum deprivation (Lu et al. [67] ). Moreover, the antiapoptotic protein B-cell 
lymphoma/leukemia-2 (Bcl-2) was shown to be upregulated in GPR12-PC12, GPR12-CHO, and 
GPR12-HEK293 cells (Adams and Cory [2] ; Lu et al. [66] , [67] ). Furthermore, endogenously 
expressed hippocampal GPR12 showed the ability to increase cell proliferation in the presence of 
SPC (Ignatov et al. [44] ). All these results suggest that GPR12 may participate in the regulation 
of cell proliferation. 
 
Additional investigations are clearly needed to understand the role of GPR3, GPR6, and GPR12 
in cell survival and proliferation in specific cells and tissues. The modulation of these receptors 
may impact neurological or oncological processes related to abnormal cell regulation. 
  
Additional neural roles of GPR3 and GPR12 
 
Because of their high expression in specific brain regions, GPR3 and GPR12 have attracted the 
attention of academic researchers and pharmaceutical companies working on related neurological 
fields. 
 
The role of GPR3 was studied in emotional disorders by Valverde and coworkers (Valverde et al. 
[114] ). This receptor is highly expressed in hippocampus, habenula, cortex, and amygdala, 
regions tightly involved in behavioral paradigms. They found that GPR3−/− mice exhibit anxiety-
like behavior in the open-field and the elevated plus maze. In forced swim and tail suspension 
tests, GPR3 ablation in mice generated an increase in immobility time indicating depression-
related behaviors. Furthermore, increased aggressiveness was detected in GPR3−/− mice in the 
resident-intruder test. These results indicate that GPR3 ablation affects stress and mood 
responses. The authors suggest that one reason behind these behavioral results is that variation in 
monoamine neurotransmitter levels in different brain regions may accompany this deletion 
(Valverde et al. [114] ). 
 
The same research group later reported that GPR3 may regulate behaviors associated with the 
early phases of cocaine reinforcement (Tourino et al. [111] ). GPR3−/− mice showed cocaine-
elicited hyperlocomotor responses, enhancement in the rewarding effects in the conditioned 
place preference (CPP) paradigm and increased reinforcing responses in the self-administration 
models, compared to WT littermates. This work suggests a possible contribution of GPR3 to 
drug addiction (Tourino et al. [111] ). 
 
The high expression of GPR12 in the limbic system, brain region that controls physiological 
functions such as memory, emotion or behavior, triggered the exploration of this orphan receptor 
in such functions. A patent from Helicon Therapeutics claims that GPR12 has a role in regulating 
long-term memory (Peters et al. [88] ). Suppression of hippocampal or amygdala GPR12 in mice 
caused a significant increase in contextual long-term memory formation, but no differences in 
short-term memory. Based on these results, they propose that inhibition of GPR12 may be a 
useful therapeutic approach for the treatment of long-term memory defects. 
 
On the other hand, Frank and coworkers showed no explicit correlation between GPR12 and 
emotional related behaviors. GPR12−/− and WT mice exhibited comparable results in tests for 
anxiety-related, depression-like, and locomotor activities (Frank et al. [26] ). 
 
The relevance of these orphan receptors in emotional, behavioral, or anxiety responses offers 
novel opportunities for investigating the neurological implication of these receptors. In addition, 
a role for GPR3 in cocaine addiction has been suggested, opening the door for further 
investigation in drug addiction. 
  
Functions outside the brain 
 
Besides their clear impact in the CNS, their expression in peripheral tissue along with possible 
upregulation under certain pathological conditions has led researchers to explore the biological 
role of GPR3, GPR6, and GPR12 in other diseases such as obesity, dyslipidemia, and ovary 
aging. 
  
Metabolic disorders 
 
Obesity is one of the major global healthcare burdens worldwide. Consequently, numerous 
approaches are currently under evaluation in the search of potential treatments. The cannabinoid 
receptor CB1 appeared to be a potential target for this disease decades ago (Serrano et al. [101] ). 
The phylogenetic relation of GPR3, GPR6, and GPR12 with the cannabinoids attracted 
researchers to explore the role of these orphan receptors in metabolic disorders. Thus far, only 
one study has shown a relation between GPR3 and late-onset obesity, whereas diverse reports 
have examined how GPR12 interplays in these pathologies (Bjursell et al. [12] ; Frank et al. [26]; 
Godlewski et al. [32] ). A patent also claimed the use of GPR6 inverse agonists in the treatment 
of obesity (Beeley et al. [9] ). 
 
Kunos and coworkers identified a link between GPR3 weight gain and thermogenesis in old mice 
(Godlewski et al. [32] ). In these studies, mice lacking GPR3 and maintained on standard chow 
diet showed an obese phenotype after 5 months of life. In fact, 1-year-old GPR3−/− subjects 
displayed higher adiposity indexes and body weight in addition to reduced energy expenditure 
and lower body temperature. Further evaluation of these metabolic profiles led them to identify a 
dysfunction in interscapular brown adipose tissue (iBAT) along with lower expression of UCP1 
(uncoupling protein 1), tightly involved in BAT heat generation (Godlewski et al. [32] ). These 
findings suggest that GPR3 deficiency in mice impaired their ability to generate heat by non-
shivering thermogenesis. In agreement, previous studies had already associated late-onset obesity 
with decreased thermogenesis due to a programed loss of function of iBAT (Waalen and 
Buxbaum [116] ; Rogers et al. [96] ). Therefore, these results indicate that GPR3 has a 
significant function in the thermogenic response of iBAT and may represent a new therapeutic 
target in age-related metabolic disorders. 
 
Interestingly, and despite the lack of further metabolic studies, a patent from Arena 
Pharmaceuticals, Inc. claimed the use of GPR6 inverse agonists for the treatment of clinical 
obesity or overweight disorders in mammals (Beeley et al. [9] ). In their studies, the previously 
mentioned compound ARE112 (Figure 8) was able to reduce body weight and food intake after 
intraperitoneal treatment in rats maintained on standard chow diet. 
 
On the other hand, a patent from AstraZeneca claimed the potential use of GPR12 modulators as 
appetite control agents in murine obesity models (Brennand et al. [14] ). A few years later, 
researchers from the same company published the first article clearly associating GPR12 with 
metabolism (Bjursell et al. [12] ). They studied food intake, respiratory metabolism, body 
composition, locomotor activity, and body temperature in mice deficient of GPR12. In these 
experiments, GPR12−/− mice showed higher body weight, body fat mass, and were dyslipidemic 
when compared with their WT littermates. The obesity observed in these mice was related to 
lower energy expenditure since other parameters, such as food intake or physical activity, 
remained unaltered. These findings suggest that GPR12 may have a role in energy homeostasis, 
consequently affecting lipid metabolism. It is worth mentioning that these studies were 
conducted in 3-12 weeks-old mice, therefore, these results are not related to aging as in the case 
of GPR3. 
 
Later studies from the same group of researchers were not able to confirm the relevance of this 
receptor in the metabolism of GPR12−/− mice (Frank et al. [26] ). No significant changes were 
observed in body weight of GPR12 deficient mice fed with chow or high-fat diets. Little 
differences were found in other metabolic parameters. Therefore, more research is clearly needed 
to understand the role of GPR12 in obesity and related processes. 
 
In addition, the Japanese company Teijin Pharma Limited patented a method for screening 
molecules targeting GPR12 in order to identify Nesfatin-1-like substances for food intake 
regulation (Mori and Eguchi [79] ). Nesfatin-1 is a neuropeptide, mainly produced in the 
hypothalamus, which is involved in the control of energy homeostasis related with food 
regulation and water intake (Oh et al. [83] ; Brailoiu et al. [13] ; Dore et al. [24] ). The inventors 
of this patent identified GPR12 as a Nesfatin-1 receptor (Mori and Eguchi [79] ), and therefore 
based their screening method on these findings. 
 
In summary, several studies have suggested a relationship between GPR3/6/12 and metabolic 
syndromes. However, further exploration of these orphan receptors in the regulation of energy 
homeostasis are needed to fully understand their roles in obesity, dyslipidemia, and related 
pathologies. 
  
Oocyte maturation 
 
Mammalian oocytes arise and enter meiosis during embryonic development but arrest at 
prophase I until reproductive maturity (Sánchez and Smitz [100] ). During the menstrual cycle, 
the oocyte completes growth achieving meiotic competence in response to a pre-ovulatory surge 
of luteinizing hormone (LH) from the pituitary gland that stimulates meiotic resumption to the 
metaphase II stage (Li and Albertini [61] ). It is well recognized that maintenance of meiotic 
arrest depends on high levels of intracellular cAMP in the oocyte (Mehlmann et al. [73] ; 
Kalinowski et al. [49] ), however, the underlying mechanisms are not fully understood. 
 
Mehlmann and coworkers discovered that the constitutively active receptor, GPR3, is directly 
related to these high levels of cAMP, and therefore it is crucial for the regulation of meiosis 
(Mehlmann et al. [74] ; Freudzon et al. [30] ; Mehlmann [72] ). In these studies, oocytes from 
GPR3−/− mice were unable to maintain meiotic arrest. Instead, they underwent spontaneous 
resumption of meiosis in the absence of an LH surge. Antral follicles from GPR3 WT mice 
showed prophase-arrested oocytes whereas antral follicles from GPR3−/− ovaries presented 
oocytes with metaphase II chromosomes and a polar body. In addition, an injection of GPR3 
RNA into the oocytes from mice lacking GPR3 was able to prevent resumption of meiosis 
(Mehlmann et al. [74] ). 
 
The expressions of GPR3, GPR6, and GPR12 have been investigated in the ovary, oocytes, and 
follicles of different species. In the mouse oocyte, not only GPR3 (Mehlmann et al. [74] ; 
Hinckley et al. [37] ), but also GPR12 (Hinckley et al. [37] ) were found, however, only GPR3 
proved to be essential to maintain meiosis arrest. On the other hand, in the rat oocyte, only 
GPR12 expression was detected (Hinckley et al. [37] ). This study provides evidence that GPR12 
is required to preserve the elevated cAMP levels that prevent meiosis resumption in rat oocytes 
(Hinckley et al. [37] ). Porcine oocytes show analogous results, displaying high GPR3 expression 
at different stages during porcine oocyte maturation (Yang et al. [119] ). Findings from another 
group, reported the cloning of GPRx, a receptor closely related to GPR12, in frog (Xenopus 
laevis and Xenopus tropicalisc) oocytes and zebrafish (Danio rerio) oocytes (Rios-Cardona et al. 
[95] ; Nader et al. [80] ). Most importantly, studies in human oocytes revealed that RNA 
encoding GPR3, but not GPR6 or GPR12, is expressed (DiLuigi et al. [23] ). In summary, 
according to expression patterns, GPR3 is the most relevant target for the oocyte maturation 
process. 
 
Further investigations pointed towards the therapeutic potential of GPR3 in fertility disorders. 
Ledent and collaborators observed that aging mice lacking GPR3 exhibit a significant fertility 
decrease (Ledent et al. [60] ). GPR3−/− mice showed a progressive decrease in litter size with 
advancing maternal age. In addition, these female mice displayed lower developmental capacity 
of embryos, an elevated number of fragmented oocytes, and more signs of reproductive aging. 
Therefore, GPR3-deficient mice may serve as a premature ovarian failure animal model. 
 
Two other reports examined the role of GPR3 in premature ovarian failure in American (Kovanci 
et al. [55] ) and Chinese women (Zhou et al. [124] ), respectively. Kovanci and coworkers 
examined whether GPR3 mutations were present in a group of 82 American Caucasian women. 
Similarly, Zhou and collaborators explored the coding region of GPR3 in 100 Chinese patients. 
In neither study could direct genetic evidence be found to confirm GPR3’s relation to premature 
ovarian failure (Kovanci et al. [55] ; Zhou et al. [124] ). Whether GPR3 function and/or 
expression is upregulated in the ovary of these patients remain to be elucidated. 
 
In summary, over the last decade, diverse investigations have supported the role of GPR3 in the 
maintenance of meiotic arrest in oocytes. While GPR6 was not detected in oocytes, GPR12 
showed meiotic relevance, but only in rats. Therefore, efforts should be focused on additional 
studies in human ovaries to further validate the therapeutic value of GPR3 in fertility disorders. 
  
Summary and future perspectives 
 
Despite their cloning nearly 30 years ago, it has been only in the last decade that research on the 
therapeutic values of GPR3, GPR6, and GPR12 has begun. Numerous academic research groups 
and pharmaceutical companies are currently focusing their efforts on a better understanding of 
the therapeutic role of these receptors. 
 
These three orphan receptors are part of the MECA cluster of Class A GPCRs. Because of this 
phylogenetic relation, GPR3, GPR6, and GPR12 share a high percentage of homology with the 
cannabinoid and the lysophospholipid receptors. 
 
GPR3, GPR6, and GPR12 are highly constituvely active GPCRs. In a variety of cell lines, they 
trigger increases in intracellular cAMP that are comparable in amplitude to activated receptors. 
In fact, this ability to extensively activate adenylyl cyclase defines their physiological relevance 
in particular processes. 
 
Despite efforts to identify putative endogenous ligands for GPR3, GPR6, and GPR12, a 
pharmacological experimental consensus has not yet been reached. This, in turn, is delaying the 
deorphanization of these receptors (Alexander et al. [6] ). Differential GPCR expression among 
cell lines, G-protein-coupling promiscuity, biased agonism or functional outcome heterogeneity 
might be causing these pharmacological discrepancies. 
 
Novel druggable small molecules are emerging as modulators of these three receptors, 
nevertheless, potent and selective ligands remained to be discovered. We provide an analysis 
here of the assorted range of chemotypes reported so far. These insights may help to facilitate the 
elucidation of pharmacophoric structural features and contribute to future rational design of new 
molecules able to selectively bind GPR3, GPR6, and/or GPR12. 
 
The pathophysiological relevance of these orphan receptors stems mainly from their high 
expression in the CNS. In certain brain disorders, the expression of these receptors is upregulated 
and their pharmaceutical intervention may offer a promising therapeutic strategy. As summarized 
in this review, numerous studies suggest the participation of GPR3, GPR6, and GPR12 in a wide 
range of neurological conditions. Neurodegenerative diseases such as AD, PD, HD, or MS, and 
neural processes such as neurite outgrowth or instrumental conditioning have been proven to be 
impacted in different ways by genetic ablation in vitro or in vivo of GPR3, GPR6, and/or 
GPR12. 
 
It is interesting to highlight that besides their structural similarities, different expression patterns 
and particular structural differences define their independent genetic implications in each 
particular disease. Differences among species need also to be considered when evaluating the 
potential of these GPCRs. For instance, as previously mentioned, differential expression of 
GPR3 and/or GPR12 has been detected in human, mouse and rat oocytes (Hinckley et al. [37] ; 
DiLuigi et al. [23] ). 
 
Because of their expression in peripheral tissues, GPR3 and GPR12 may be potential targets for 
metabolic and ovary-related pathological conditions. However, much work needs to be 
conducted to investigate their role under other pathophysiological processes at both central and 
peripheral levels. 
 
Pharmacological intervention at these receptors represents a promising strategy for the treatment 
of aforementioned disorders. Even if the lack of accessible pharmacological tools is hampering 
their appropriate characterization, the knowledge gained so far clearly suggests that modulation 
of GPR3, GPR6, and/or GPR12 will be beneficial in particular diseases. For example, the 
outstanding research carried out on the elucidation of the role of GPR3 in the amyloid pathology 
indicates that selective blockage of the GPR3 G-protein independent β-arrestin2 signaling 
pathway will reduce beta amyloid plaque formation (Thathiah et al. [107] ). In contrast, 
pharmaceutically targeting GPR3 in fertilization processes may require activation of this 
receptor, ideally through a peripherally restricted mechanism (Mehlmann et al. [74] ). 
 
Overall, this work aims to emphasize the therapeutic potential of GPR3, GPR6, and GPR12 
through a comprehensive first summary of the state of the art in this field. 
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